<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PSA Rising Prostate Cancer Blog &#187; Casodex</title>
	<atom:link href="http://www.psa-rising.com/blog/category/pca/pca-tx/hormonal/casodex/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.psa-rising.com/blog</link>
	<description></description>
	<lastBuildDate>Wed, 25 Nov 2009 18:36:49 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.6</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Sandoz launches generic version of Casodex® tablets</title>
		<link>http://www.psa-rising.com/blog/2009/07/sandoz-launches-generic-casodex/</link>
		<comments>http://www.psa-rising.com/blog/2009/07/sandoz-launches-generic-casodex/#comments</comments>
		<pubDate>Thu, 09 Jul 2009 07:50:41 +0000</pubDate>
		<dc:creator>jacquie strax</dc:creator>
				<category><![CDATA[Casodex]]></category>
		<category><![CDATA[Hormonal-ADT]]></category>
		<category><![CDATA[PCa Treatments]]></category>

		<guid isPermaLink="false">http://www.psa-rising.com/blog/?p=1647</guid>
		<description><![CDATA[Princeton, New Jersey; July 9, 2009 &#8212; Sandoz today announced the introduction of bicalutamide tablets, USP a generic equivalent of Casodex®, in the United States. Bicalutamide is an androgen receptor inhibitor indicated for use in combination therapy with a luteinizing hormone-releasing hormone (LHRH) analog for the treatment of Stage D2 metastatic carcinoma of the prostate. [...]]]></description>
		<wfw:commentRss>http://www.psa-rising.com/blog/2009/07/sandoz-launches-generic-casodex/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Generic Casodex: Tentative US Approval</title>
		<link>http://www.psa-rising.com/blog/2009/01/generic-casodex-tentative-us-approval/</link>
		<comments>http://www.psa-rising.com/blog/2009/01/generic-casodex-tentative-us-approval/#comments</comments>
		<pubDate>Thu, 08 Jan 2009 20:17:16 +0000</pubDate>
		<dc:creator>Steve</dc:creator>
				<category><![CDATA[Casodex]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[Prostate Cancer]]></category>

		<guid isPermaLink="false">http://www.psa-rising.com/blog/2009/01/generic-casodex-tentative-us-approval/</guid>
		<description><![CDATA[On December 24, 2008 the US Food &#38; Drug Administration granted tentative approval to Accord Healthcare&#8217;s bicalutamide.
Accord is a subsidiary of Intas Pharmaceuticals, Ltd., an Indian company. Accord&#8217;s function is licensing and marketing.

According to the FDA, this is the definition of &#8220;tentative approval&#8221;:
&#8220;If a generic drug product is ready for approval before the expiration
of any [...]]]></description>
		<wfw:commentRss>http://www.psa-rising.com/blog/2009/01/generic-casodex-tentative-us-approval/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
